EGFR and non-small cell lung carcinoma: Second, KRASmut NSCLC cell models display a range of sensitivity to EGFR and AURKA inhibition; however, the degree of sensitivity in vitro does not correspond directly to expression of the EGFR or AURKA protein, or TP53 mutation status.